Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2395
Peer-review started: August 9, 2014
First decision: September 15, 2014
Revised: October 3, 2014
Accepted: November 19, 2014
Article in press: November 19, 2014
Published online: February 28, 2015
Processing time: 204 Days and 6.6 Hours
AIM: To investigate the efficacy and safety of transarterial chemoembolization (TACE)-based multimodal treatment in patients with large hepatocellular carcinoma (HCC).
METHODS: A total of 146 consecutive patients were included in the analysis, and their medical records and radiological data were reviewed retrospectively.
RESULTS: In total, 119 patients received TACE-based multi-modal treatments, and the remaining 27 received conservative management. Overall survival (P < 0.001) and objective tumor response (P = 0.003) were significantly better in the treatment group than in the conservative group. After subgroup analysis, survival benefits were observed not only in the multi-modal treatment group compared with the TACE-only group (P = 0.002) but also in the surgical treatment group compared with the loco-regional treatment-only group (P < 0.001). Multivariate analysis identified tumor stage (P < 0.001) and tumor type (P = 0.009) as two independent pre-treatment factors for survival. After adjusting for significant pre-treatment prognostic factors, objective response (P < 0.001), surgical treatment (P = 0.009), and multi-modal treatment (P = 0.002) were identified as independent post-treatment prognostic factors.
CONCLUSION: TACE-based multi-modal treatments were safe and more beneficial than conservative management. Salvage surgery after successful downstaging resulted in long-term survival in patients with large, unresectable HCC.
Core tip: The aim of this study was to investigate the efficacy of transarterial chemoembolization (TACE)-based multimodal treatment in patients with large hepatocellular carcinoma. The primary findings of this study were as follows: (1) The overall survival was significantly longer in the treatment group than in the conservative group; (2) Survival benefits were observed not only in the surgical treatment group (TACE + resection or transplantation) compared with the localized treatment group (TACE + ablation/radiotherapy) but also in the combination treatment group compared with the TACE-only group; and (3) Objective response, surgical treatment, and multi-modality were independent factors for survival.